AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02810626 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BrightMatter™ products
Description: BrightMatter™ Plan (BMP): BMP is a software that enables surgeons to plan their neurosurgery preoperatively. BMP automatically generates whole brain tractography and highly accurate fusion of anatomical MRI and DTI images.~BrightMatter™ Bridge (BMB):BMB involves offering SMI's MRI expertise to ensure a smooth workflow in neuroimaging including DTI to ensure optimized protocols are used to acquire the DTI images. Once the images are acquired, they are evaluated for their quality in real time using a quality control (QC) algorithm. The QC allows quality assessment of DTI images at the time-of-scan allowing for immediate correction while the patient is still there and reduces the need for patient re-scan.~BrightMatter™ Guide (BMG): BMG is a neuro-navigation system that utilizes the DTI information and the trajectory planned by the surgeon in BMP pre-operatively, but bringing it into the operating room intraoperatively.
Study NCT03302559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen
Description: Sunscreen broad spectrum sun protection factor (SPF) 35 topically in the morning and as needed.
Study NCT03302559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin Imaging
Description: Non-invasive in vivo skin imaging will be taken with the VivoSight Dx Optical Coherence Tomography (OCT) and VivaScope 1500
Study NCT00676585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline
Study NCT00676585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone 100mg
Study NCT05017493 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Xagrotin
Description: A group of patients were treated with Xagrotin with or without standard of care, the control group received stadard of care
Study NCT04295499 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: soft (hydrophilic) contact lens
Description: The intervention is a daily wear soft contact lens
Study NCT04295499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: soft (hydrophilic) contact lens
Description: The intervention is a daily wear soft contact lens
Study NCT00563433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ofloxacin
Description: 400 mg twice a day for 14 days
Study NCT00563433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MSI-78
Description: 1%/2% topical cream twice a day for 14 days
Study NCT03100253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 8 mg/kg i.v. every 4 weeks OR 162 mg s.c every seven days
Study NCT03100253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: a. Etanercept if initial failure to monoclonal antibodies: infliximab, adalimumab, golimumab or certolizumab
Study NCT03100253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: infliximab if initial failure to the receptor fusion protein, etanercept.
Study NCT03100253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: adalimumab if initial failure to the receptor fusion protein, etanercept.
Study NCT03100253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golimumab
Description: golimumab if initial failure to the receptor fusion protein, etanercept.
Study NCT03100253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Certolizumab Pegol
Description: Certolizumab Pegol if initial failure to the receptor fusion protein, etanercept.
Study NCT00689663 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Randomized to three arm.
Study NCT01094366 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paracervical Block
Description: Subject receives 20 mL paracervical block with 18 mL of 1% Lidocaine solution buffered with 2 mL 8.4% sodium bicarbonate for pain control.
Study NCT01094366 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Paracervical Block
Description: In the non-intervention group, the surgeon performs a sham PCB during which 2 mL buffered lidocaine solution are injected at the tenaculum site, after which a capped needle gently simulates the standard PCB procedure.
Study NCT04714099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Cyclosporine A
Description: In our study we used 0.05% CsA prepared in castor oil by transferring (20ml ) of sterile castor oil in a sterile glass vial under laminar flow, removing a volume (400ul)of oil with micropipette (sterile tips), and replacing this volume with an equal volume of alcoholic CsA solution \[200mg cyclosporine in 8 ml ethanol (96%)\] under laminar flow.
Study NCT04714099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02971605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 25 mg/70 kg Psilocybin
Study NCT00437281 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00437281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Orally-administered pregabalin
Study NCT03244995 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mind-Body Intervention Procedure
Description: Undergo CBMB program
Study NCT03244995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03244995 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03244995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03244995 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04036578 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: A 12-week PFMT bio-assisted surface electromyographic program
Study NCT03875391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Drug: Oxytocin nasal spray
Study NCT03875391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo nasal spray
Study NCT02915510 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glycomacropeptide-based protein substitute
Study NCT03635684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Subcutaneous infusion of Acetaminophen over 20 to 30 minutes, with evaluation of:~* local side effects;~* pain and/or fever;~at time of infusion, after 30 minutes, 60 minutes and 180 minutes.
Study NCT02613065 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Consumption of NOW Foods eggwhite protein shake
Description: Consumption of NOW Foods egg white protein shake at beginning of 3 daily meals that in total, is approximately 20% of caloric needs.
Study NCT02613065 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Consumption of NOW Foods maltodextrin shake
Description: Consumption of NOW Foods maltodextrin shake at beginning of 3 daily meals that in total, is approximately 20% of caloric needs.
Study NCT02261571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moxibustion
Description: In the moxibustion treatment group, 3 moxibustion, 3 acupoints(CV12, CV8, CV54) will be heated with indirected moxibustion.~The moxibustion will be removed when the patient feel hotness and require remove them
Study NCT02022371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted biopsies of the prostate
Description: Multiple biopsies from a MRI lesion for analysis of intratumour heterogeneity
Study NCT04128449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: docosahexaenoic acid
Description: 5 dragees every 24 hours
Study NCT04128449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 dragees every 24 hours
Study NCT03760510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tube Fastener
Description: Endotrachel tube secured with tube fastener
Study NCT03760510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adhesive Tape
Description: Endotracheal tube secured with adhesive tape.
Study NCT01491659 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Idoform Plus
Description: orally once daily
Study NCT01491659 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally once daily
Study NCT01488019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Perforomist-Placebo
Description: Placebo vehicle, 2mL, twice daily for 52 weeks
Study NCT01488019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perforomist, nebulization, COPD
Description: Perforomist, 20 mcg/2 mL, twice daily for 52 weeks
Study NCT04235647 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nurse led tutorial on lifestyle management and pedometer hand-out
Description: Individual 10-minute nurse-led tutorial with distributed handouts on the health benefits of regular physical activity and pedometer hand-out
Study NCT04235647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse led tutorial on lifestyle management and pedometer hand-out
Description: Individual 10-minute nurse-led tutorial with distributed handouts on the health benefits of regular physical activity and pedometer hand-out
Study NCT04235647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Steps goal setting and supporting phone calls
Description: A goal of minimum 7000 steps per day, phone calls to assess the goal meeting and to support goal achievement every 2 weeks
Study NCT01332110 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Knee abduction moment-reducing footwear
Description: Patients in each study group will be asked to run using their assigned footwear at least 3 times per week (minimum 15 km per week) for six weeks. Each patient will document their perceived knee pain each week throughout the six week intervention.
Study NCT01332110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee abduction moment-reducing footwear
Description: Patients in each study group will be asked to run using their assigned footwear at least 3 times per week (minimum 15 km per week) for six weeks. Each patient will document their perceived knee pain each week throughout the six week intervention.
Study NCT03682783 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fundus Image
Description: Fundus image of optic nerve
Study NCT00235833 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 40 mg every other week (eow), subcutaneous (sc)
Study NCT01344395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine and ketorolac
Description: The RK-group receives four intra-articular injections via catheter with a total volume of 40 ml (380 mg ropivacaine and 60 mg ketorolac) combined with 4 intravenous injections of saline during 24 hours postoperatively
Study NCT01344395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: The K-group receives four intra-articular injections via catheter with a total volume of 40 ml saline combined with 4 intravenous injections of ketorolac (total 60 mg) during 24 hours postoperatively
Study NCT03982082 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Undergo physical therapy
Study NCT03982082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03982082 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Undergo ultrasound via MuscleSound technology
Study NCT05531994 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast sodium oral thin films with water (T)
Description: Single-dose montelukast sodium oral thin film 5mg under fed condition with water 240 mL
Study NCT05531994 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast sodium chewable tablets with water (R)
Description: Single-dose montelukast sodium chewable tablet 5mg under fed condition with water 240 mL
Study NCT00360308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00926289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: Telmisartan 80mg
Study NCT00926289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Telmisartan 80mg
Study NCT00926289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide25mg
Study NCT02734615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSZ102
Description: LSZ102
Study NCT02734615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: LEE011
Study NCT02734615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: BYL719
Study NCT04537325 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RenalGuard system
Description: Periprocedural intravenous hydration matched to urinary output.
Study NCT04571957 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT00780715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide MR
Description: 30mg daily increased to 60mg if HbA1c > 7% at 3 months
Study NCT00780715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 100mg daily for 6 months
Study NCT00780715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 30mg daily , increased to 45mg daily if HbA1c >7% at 3 months. 6 months duration
Study NCT00780715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg od for 1 week, bd for 1 week, 1g mane 500 mg nocte 1 week, 1g bd there after. Total of 6 months treatment
Study NCT01950754 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: standing with both feet
Study NCT01950754 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: descent of the platform
Study NCT01950754 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: standing on the platform, feet together and always with simultaneous performance of a task of mental count
Study NCT00756028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patients receiving short protocol IVF/ICSI-treatment.
Description: Injection s.c. Orgalutran® (Ganirelix)0.25 mg once daily from day 5 of FSH-stimulation until HCG-day
Study NCT00756028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long protocol
Description: Patients receiving long protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-agonist (Synarela®:Nafarelin)
Study NCT04447833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stromal Stem Cells - KI-MSC-PL-205
Description: Allogeneic bone marrow derived mesenchymal stromal stem cells (MSCs).
Study NCT00111189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo every 4 wk up to 24 mo
Study NCT00111189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate
Description: 25, 50, 75 or 100 mg eq every 4 wk for up to 24 mo
Study NCT03221946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium
Description: tablet of 50mg,
Study NCT03221946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Description: Transdermal patch 100 mg
Study NCT03221946 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Diclofenac
Description: intra muscular injection 100mg
Study NCT00583596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device closure with AMPLATZER Duct Occluder
Description: Device closure with AMPLATZER Duct Occluder
Study NCT00583596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Objective Performance Criteria
Description: Compare results of device closure to objective performance criteria
Study NCT04318652 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methylprednisolone eyedrops
Description: instillation of methylprednisolone eye drops
Study NCT04318652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone eyedrops
Description: instillation of methylprednisolone eye drops
Study NCT01933828 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OPEN lobectomy
Description: Lobectomy and mediastinal lymph node dissection by thoracotomy with rib-spreading.
Study NCT01933828 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS lobectomy
Description: Thoracoscopic minimally invasive lobectomy with thoracoscopic mediastinal lymph node dissection without rib-spreading.
Study NCT01933828 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ROBOT-assisted lobectomy
Description: Robot-assisted lobectomy with mediastinal lymph node dissection (Robot group as clinical assignment in prospective Cohort).
Study NCT03509051 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B vaccination
Description: One intramuscular injection of Bexsero (multicomponent B vaccine) from 6 months after transplant. A second similar dose will be given 2 months later.
Study NCT04317729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fujirebio INNOTEST® HCV Ab IV assay
Description: Enzyme Immunoassay
Study NCT02888925 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mooney test
Study NCT02888925 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Benton Face Recognition test
Study NCT02888925 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Face inversion effect test
Study NCT02888925 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Face composite effect test
Study NCT02888925 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cambridge Face Memory Test
Study NCT05606640 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsychological pain assessment
Description: At baseline (T0) patients underwent the somatosensory pain assessment, joint structure and function assessment and filled in all questionnaires. During one month after baseline (T1) patients wore an activity tracker and filled in the Illness Perceptions Questionnaire and the International Physical Activity questionnaire. During one year after the baseline assessment (T2) patients filled in every month The Brief Pain Inventory, Illness Perceptions Questionnaire and the EQ-5D-5L quality of life questionnaire.
Study NCT03916237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home assessment
Description: Home assessment for environmental hazards according to protocol established by Environmental Health Watch (Healthy Home Audit https://www.ehw.org/healthy-home-audit/)
Study NCT02888925 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Matching different view test
Study NCT02888925 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Memorizing and recognition of new faces test
Study NCT00360308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E2007
Study NCT02888925 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Memorizing and recognition of new objects test
Study NCT02888925 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Recognition of celebrities and access to semantic information test
Study NCT02888925 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lobectomy
Description: In patients with anterior temporal epilepsy, at 6 to 12 months after inclusion, depending on surgery decision taken after pre-surgery conventional intercritical assessment
Study NCT04078919 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nut consumption
Description: daily consumption of 20 percent of daily calories intake from nuts (pistachio, almond and peanuts)
Study NCT04078919 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low calorie diet
Description: Low calorie diet
Study NCT04078919 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low calorie diet
Description: Low calorie diet
Study NCT02881073 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maternal plasma PlGF quantification
Description: A point of care test performed on maternal plasma, to quantify the level of the protein PlGF (placental growth factor) in the serum of the pregnant woman with suspected pre eclampsia to help the clinician in stratifying the level of further care for her in her pregnancy
Study NCT00124449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: solution, intravenous injection, monthly, 169 days~weight based:~\<60 kg = 500 mg~60 to 100 kg = 750 mg~>100 kg = 1 g
Study NCT00124449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: solution, intravenous injection, 0 mg, monthly, 169 days